Tharimmune (THAR) Registration Filing summary

Company overview and business model

• Operates as a dual-focused entity: advancing institutional blockchain adoption via Canton Coin and the Canton Network, and developing clinical-stage biotech assets in immunology and inflammation.

• Implements a Canton-centric digital asset treasury strategy, acquiring and utilizing Canton Coin as a reserve and participating as a Super Validator on the Canton Network.

• Maintains ongoing biotech R&D, including therapeutic candidates for chronic pruritus, opioid prophylaxis, and immuno-oncology targets.

Financial performance and metrics

• Closed a PIPE transaction on November 6, 2025, raising approximately $545 million in gross proceeds before fees and expenses.

• Allocated $6 million from proceeds plus all pre-closing cash for ongoing business operations; the remainder is for transaction expenses and Canton Coin acquisition.

• Last reported sale price of common stock was $2.47 per share on December 4, 2025.

Use of proceeds and capital allocation

• No proceeds from this offering will go to the company; all shares are sold by selling stockholders.

• Proceeds from the PIPE transaction are primarily allocated to acquiring Canton Coin and implementing the digital asset treasury strategy, with a portion reserved for historical business operations.